Related Experiment Video
Updated: Jun 13, 2025
08:53
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
809
5-Methoxytryptophan Alleviates Dextran Sulfate Sodium-Induced Colitis by Inhibiting the Intestinal Epithelial Damage
Yanling Wang1, Jun Li2, Qinyuan Yang3
1Department of Rheumatology and Immunology Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mediators of Inflammation
|September 12, 2024
Summary
5-methoxytryptophan (5-MTP) effectively treats colitis by reducing inflammation and protecting intestinal cells. This study shows 5-MTP inhibits immune cell infiltration and damage, suggesting its potential as a novel therapeutic agent for inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Colitis is a severe intestinal inflammatory disease impacting patient quality of life.
- Key factors include infections, ischemia, and immune cell accumulation.
- 5-methoxytryptophan (5-MTP) shows potential anti-inflammatory properties, but its role in colitis is unexplored.
Purpose of the Study:
- To investigate the therapeutic potential of 5-methoxytryptophan (5-MTP) in a mouse model of colitis.
- To elucidate the mechanisms underlying 5-MTP's anti-inflammatory effects in the gut.
Main Methods:
- Dextran sulfate sodium (DSS)-induced colitis mouse model.
- Western blot, hematoxylin-eosin staining, immunofluorescence, and TUNEL assay were employed.
- In vitro assays assessed M1 macrophage polarization and cellular inflammation.
Main Results:
- 5-MTP demonstrated significant therapeutic efficacy in treating colitis.
- 5-MTP inhibited macrophage infiltration and inflammatory factor production.
- Intestinal epithelial barrier integrity was preserved, with reduced apoptosis and M1 polarization.
Conclusions:
- 5-MTP effectively mitigates inflammation and protects intestinal epithelial tight junctions.
- The anti-apoptotic and anti-inflammatory properties of 5-MTP position it as a promising candidate for colitis treatment.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
223
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
223
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120